# Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

> **NCT00451451** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 1417 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** BG00012
- **DRUG:** Placebo
- **DRUG:** Glatiramer Acetate

## Key facts

- **NCT ID:** NCT00451451
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 1417 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451451, "Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00451451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*